Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of oral Alitretinoin (Toctino) in the Treatment of Patients with Cutaneous Lupus
2010-024131-16Phase 2Terminated
- Sponsor
- Universitätsklinikum Münster
- Start
- Feb 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of alitretinoin in cutaneous lupus erythematosus (CLE), subacute cutaneous lupus erythematosus (SCLE), discoid lupus erythematosus (DLE) and 2 more, sponsored by Universitätsklinikum Münster. Primary endpoint: Primary efficacy response rate. Started Feb 2011; status: terminated.
02
Drugs
alitretinoin
03
Conditions
cutaneous lupus erythematosus (CLE)subacute cutaneous lupus erythematosus (SCLE)discoid lupus erythematosus (DLE)Lupus Erythematosus Tumidus (LET)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2010-024131-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024131-16.